ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Br…

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...

AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...
Yahoo

Enhertu, with new OK, set to supplant chemo in HER2-low breast cancer

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug Administration on Monday expanded ...

Roche Gets Expanded FDA Approval for Breast-Cancer Test

Roche received expanded approval from the Food and Drug Administration for a test to diagnose breast cancer. The pharmaceutical company said Monday that the FDA approved the PATHWAY HER2 (4B5) test ...
Seeking Alpha

AstraZeneca's Enhertu, pertuzumab combo improves breast cancer treatment in trial

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer, ...
Nasdaq

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following ...

Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...
Yahoo

AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer

The Food and Drug Administration on Friday approved AstraZeneca and Daiichi Sankyo’s Datroway for use in people with a common type of breast cancer that has advanced despite two earlier lines of ...
Reuters

EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment for ...
AOL

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

(Reuters) -AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.
pharmaphorum

Appeals court turns Enhertu patent dispute on its head

The federal appeals court has now reversed the 2022 verdict upholding the '039 patent, thereby vacating the Texas court's ...
Fierce Pharma

Daiichi Sankyo prevails on appeal in long-running ADC patent battle with Seagen, flipping prior $41.8M verdict

Daiichi Sankyo has emerged victorious in appeals court, flipping a prior multimillion-dollar patent verdict on its head and ...
Khaleej Times on MSN

US FDA approves AstraZeneca, Daiichi's breast cancer drug as first-line treatment

The US Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line ...